New Delhi, Oct. 22 -- OpenAI Expands Its Presence in AI-Driven Drug Development

OpenAI has announced its acquisition of biotechnology software startup Orchestra Bio, strengthening its presence in artificial intelligence-powered drug discovery and pharmaceutical research.

Announced in October 2026, the acquisition aims to integrate Orchestra Bio's technology and expertise into OpenAI's Rosalind platform, connecting scientific AI capabilities with complex pharmaceutical development workflows.

The move signals OpenAI's growing ambition to support not just scientific discovery but also the operational processes required to bring new medicines to patients. Financial terms were not disclosed.

Why Did OpenAI Acquire Orchestra Bio?

Drug deve...